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physician’s door: will mobile technology improve
detection?
Perttu J Lindsberg1,2*, Lauri Toivonen3 and Hans-Christoph Diener4Abstract
The rising numbers of people with atrial fibrillation (AF) carry a heavy toll on our graying population. Epidemiological data
suggest that AF exists in 1 in 10 individuals aged older than 80 years. The risk of embolic stroke increases along with
well-known cardiovascular risk factors. Should there be systematic screening for the elderly? Although 1 in 10 is a huge
hit rate in screening for any major illness, the initiative for such programs in AF remains in ‘research and development’.
At present, cardiologists can utilize implantable loop recorders in patients referred for specialist consultation. Novel
technologies are also available, including cloud-based, algorithm-assisted, non-invasive monitoring patches, which allow
extended observation periods.
What about people in the community without a recognized need for cardiologic investigation? Mobile technology has
made detection of pulse irregularity possible without medical attention. Smartphone apps enable opportunistic rhythm
monitoring, but true arrhythmias need to be medically verified. AF may be the first common disorder to be effectively
screened for by mobile technology. In the spirit of proactive campaigns such as ‘Know Your Pulse’, we should prepare for
rapidly increasing reports of various pulse irregularities.
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medical applicationThe purpose of this article is to promote more vigorous
detection of undetected, quiet persistent or paroxysmal
AF. Lack of efficient screening and absence of versatile
AF detection technology comprise an important bottleneck
in the prevention of first strokes. We believe that more ag-
gressive societal programs and technological innovations in
self-administered AF detection could lead to a reduced bur-
den of embolic strokes in the face of the AF epidemic re-
lated to the ‘graying’ of western civilization.Criteria for systematic AF screening
AF fulfills key premises for a condition to be systematic-
ally screened for in the healthy population [1,2]. We
comment on a few of these in Table 1.* Correspondence: perttu.lindsberg@hus.fi
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unless otherwise stated.Modes and methods of AF detection
Methods for initial detection of AF are dependent on
the presence or absence of symptoms. In asymptomatic
subjects, pulse palpation and interpretation of incidental
12-lead or bipolar ECGs are the most frequently used
methods. One study found that pulse palpation by a
practice nurse plus 12-lead ECG reading by a general
practitioner is an efficient means of screening older patients
for AF [16]. However, inviting elderly patients with or
without risk factors to attend for a 12-lead ECG is not
cost-effective, as it produces small benefit at the cost of
high workload. Instead, campaigns promoting regular pulse
palpation, such as Know Your Pulse, have been devised.
In symptomatic patients and in those suspected of having
paroxysmal AF or cryptogenic stroke, AF is often detected
and confirmed by serial ECGs or Holter monitoring for 1
or 2 days. In those with infrequent paroxysms, long-term
continuous ECG by automatic (for asymptomatic patients)
or patient-activated symptomatic event loop recorders
might be needed. Quantification of arrhythmia burden withral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary of key premises for a condition to be systematically screened for in the healthy population
Criteria for systematic AF screening1.2
AF and stroke as societal health challenges
1) AF is common, affecting approximately 5% of adults aged 65 years and older, and 10% of those older than 80 years [3].
One in four individuals is now being projected to develop the condition in their lifetime [4]. Investigators of one
community survey reported a rise of 12.6% in the incidence of AF during the past 2 decades, and projected that
15.9 million people in the USA will have the disorder by 2050 [5]
2) AF increases the risk for ischemic stroke by approximately fivefold. In the UK, findings from the SAFE study [6] showed
a baseline prevalence of AF of 7.2% in patients aged 65 years and older, with an increased prevalence in men (7.8%)
and in those aged 75 years and older (10.3%), and a yearly incidence of new AF of about 1.6%. AF causes 15% of all
strokes, and 30% of those whose strokes occur after the age of 80 years in the US population [3,4]
3) AF constitutes a public health burden by triggering prevalent embolic strokes, and it frequently leads to impaired
quality of life, resulting in high healthcare costs. The cost of stroke is substantial. In the UK, mean censor-adjusted
5-year hospital costs after stroke were $25,741 [7], but the lifetime costs have been estimated to be substantially
higher; for example, $130,000 after ischemic stroke in Finland [8]
Possibilities for AF screening
4) Individuals of advanced age – for example, 70 and 80 years old –are a suitable target population for screening, as
the incidence of AF at older ages is substantial
5) There is an early or latent stage, in which patients with AF are commonly asymptomatic, but they may progress to
manifest cardiac problems and sudden cardioembolism and stroke. Further, AF may be preceded by subclinical atrial
tachyarrhythmias, which are associated with significantly increased risk of stroke and systemic embolism [9]
6) The diagnosis is simple using widely available, non-invasive tools such as ECG and Holter-ECG
Recommendations for treatment
7) There are already agreed policies in place for treatment of incidental AF in asymptomatic individuals, or in patients
following symptoms or stroke. Several accepted interventions are available, which can correct the underlying cardiac
rhythm disturbance of AF, including pharmacologic cardioversion, electrical cardioversion, and catheter ablation [10]
8) Scoring systems (for example, the CHA2DS2-VASc score) detailed in consensus guidelines are in place to individually
guide the initiation of oral OACs in order to decrease the risk of subsequent AF-related new ischemic strokes [11].
OACs produce marked reductions in strokes; for example, up to 64% for warfarin and an estimated 77% for
dabigatran compared with placebo [11]
9) Several novel OACs, such as dabigatran, rivaroxaban and apixaban, are available, which probably reduces the
threshold of initiating long-term therapy to reduce cardioembolic strokes [12-15].
Risks and benefits
10) Potential risks of screening include development of serious hemorrhagic complications in some patients prescribed OACs.
11) Scientific evidence for the benefits and effectiveness of screening programs is still being produced. It has not yet
been demonstrated that systematic screening for AF improves outcome
AF atrial fibrillation, ECG electrocardiogram, OAC oral anti-coagulant, SAFE Screening for Atrial Fibrillation in the Elderly.
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recorder; ILR) may be used in attempt to provide an indi-
vidual estimate of AF burden and related stroke risk. In
some patients with existing cardiac arrhythmia, recorded
or remote surveillance of implanted cardiac arrhythmia
devices may provide a diagnosis. Newer methods include
modified sphygmomanometers or finger-probe devices.
Why is systematic screening for AF not carried
out in at-risk populations?
AF not only increases the risk for ischemic stroke by
approximately fivefold, but AF-related strokes result in
more deaths and disability than strokes from other
causes [17]. Despite this, the US Preventive Services Task
Force and the UK National Screening Committee have
no policy recommendation for systematic or opportunistic
(for example, pulse recording with follow-up ECG) screen-
ing for AF in primary care or in the healthy population.Detection of AF causes discomfort for otherwise healthy
individuals and apparent added direct healthcare costs for
society. However, societal reasons for not performing more
systematic screening of AF are offset by the decreased
need for regular blood coagulation tests with newer oral
anti-coagulants (OACs), which have been demonstrated
as cost-effective [18].
Risk–benefit ratio of systematic AF screening
Could enhanced AF screening produce more harm than
benefit? The elevated stroke risk in AF is not homogeneous,
and changes cumulatively with the presence of stroke
risk factors, as illustrated in various stroke risk stratifi-
cation schema such as CHADS2 score and the newer
CHA2DS2-VASc score [11]. These categorize patients
as having low, moderate, or high risk. Management
guidelines have traditionally recommended that pa-
tients with high or moderate risk should be given oral
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mend oral anti-coagulation for patients with intermediary
risk of CHA2DS2-VASc score 1 or 2 as well. Anti-platelet
agents can be given when oral anti-coagulation therapy
cannot be given [19].
However, this approach also requires consideration
of bleeding risk. To this end, the HAS-BLED score
(uncontrolled Hypertension, Abnormal renal/liver func-
tion, Stroke, Bleeding history or predisposition, Labile
international normalized ratio, Elderly >65 years, Drugs/
alcohol concomitantly) has been proposed as a simple
bleeding-risk assessment for patients with AF [11].
Standardized assessment of bleeding risk allows in-
formed decision-making, and alerts clinicians to poten-
tially correctable bleeding risk factors. We believe that
by applying these schemes to estimate the individual
risk/harm profile, it is possible to balance the risks and
benefits in a given patient in order to reduce their stroke
risk. Screening should always be accompanied by improved
patient management.
We are aware of the perennial challenges relating to
screening policy decisions. The exact fraction of strokes
caused by undetected AFs versus those already detected
cannot be predicted. Given the high prevalence of AF in
the elderly population, it is unlikely that opportunistic AF
screening by pulse palpation during occasional primary care
visits will essentially change the numbers of detected AF in
the target population. Campaigns such as ‘Know Your Pulse’
are important endeavors for educating the general public,
although data on their efficacy are lacking. One solution
would be to have nurses in doctors’ offices routinely take
the pulse of people aged over 70 years, who see a doctor
several times a year on average.
We are not convinced that the projected yield of pal-
pation campaigns will be satisfactory in tackling the AF
epidemic. Therefore, given the advent of novel techno-
logical advances, we encourage additional steps. To this
end, the yield from systematic population screening for
AF in healthy individuals with normal ECG was re-
cently investigated. All inhabitants in the municipality
of Halmstad (Sweden) aged 75 to 76 years were invited
to a stepwise screening program for AF [20]. In the
first step, participants underwent 12-lead ECG, and re-
ported their relevant medical history. Those with sinus
rhythm on 12-lead ECG, no history of AF, and two or
more risk factors according to CHADS2 score, were in-
vited to participate in a 2-week recording period using
a hand-held ECG, and asked to record 20 or 30 seconds of
ECG twice daily and if palpitations occurred. In total,
1,330 inhabitants were invited, of whom 848 (64%) partici-
pated. Previously undiagnosed silent AF was found in 10
(1%) of 848 individuals who recorded 12-lead ECG. Of 81
patients with known AF, 35 (43%) were not on OAC treat-
ment. Of 403 individuals with two or more risk factors forstroke who completed the hand-held ECG event record-
ing, 30 (7.4%) were diagnosed with paroxysmal AF. Thus,
75/848 (9%) of the screened population were candidates
for new OAC treatment, of whom 57 actually started
this treatment [20]. An approach for future research
would be to utilize known biomarkers of AF to comple-
ment CHA2DS2-VASc scores in selecting individuals for
AF screening.
Remote surveillance technology for AF detection
Stroke researchers are currently attempting to improve
rates of AF detection in cryptogenic stroke with continuous
automated ECG analysis at the bedside in stroke units or
with extended recordings using implantable cardiac moni-
toring devices [21]. However, we argue that given the high
prevalence of AF, physicians in general should promote
detection of silent AF in individuals well before the poten-
tially fatal or debilitating ‘index’ stroke, that is, for primary
prevention in the general population. In particular, elderly
individuals are at considerable risk of having undetected
paroxysmal or persistent AF.
Despite ILRs having been available for nearly a decade,
their use for AF screening has not become common. The
IMPACT Study was designed to investigate the clinical
benefit of combined use of home monitoring technology
and a predefined anti-coagulation plan compared with
conventional device evaluation and physician-directed
anti-coagulation in patients with implanted dual-chamber
defibrillators or cardiac resynchronization therapy devices
[22]. The event rates were presumably low, as this trial
was terminated prematurely. The trial included only
patients with existing cardiac indication and CHADS2
score of 1 or greater, and had no special focus on elderly
individuals. In addition, the control subjects were patients
monitored in accordance with guidelines for management
of patients with implanted cardiac arrhythmia devices, in
whom the rates of thromboembolic events are relatively
low. Therefore, studies on elevated cardiovascular and
thromboembolic risk in a broader population of ad-
vanced age might be better for investigating differential
efficacies in AF detection. Secular trends transform the
settings and technologies by which pulse irregularity
and newly diagnosed AF are initially detected. More
AF cases are detected outside hospitals, and more pulse ir-
regularities are probably initially detected without ECG in
asymptomatic subjects.
We postulate that AF will soon be the first major car-
diovascular disease to be detected by personal devices
that are rapidly becoming available worldwide. Currently,
lightweight insertable cardiac monitors are being man-
ufactured for capturing ECG for collapse diagnostics.
Computer-assisted decision support software used in
the clinic to detect AF has yielded a specificity of
greater than 99% and sensitivity of 87% [6]. Afib Alert®
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Drug Administration (FDA)-approved device that helps
users know when they are likely to be experiencing AF. It
allows a patient using the device to communicate informa-
tion to their doctor directly over their phone. Another ap-
plication is the ZIO® Patch (iRhythm Technologies, San
Francisco, CA, USA), an algorithm-assisted device allow-
ing cloud-based AF detection monitoring for an extended
period [23]. A doctor's prescription is generally required
for these devices; however, it is unlikely that this will pre-
vent comparable devices from eventually being distributed
to the general public by manufacturers and retailers for
considerable profits.
Self-administered irregular pulse detection:
solution or new concern?
For systematic screening to be demonstrated to be an ef-
fective intervention, it must improve the detection rate of
AF and provide benefit for those in whom AF is detected
early. This has yet to be demonstrated [24]. In view of the
high cost of systematic screening programs, it may turn
out that cost-effectiveness is difficult to attain. Further-
more, absence of AF at one screening time-point does not
preclude its later development, thus techniques usable at
any time according to the patient’s initiative will be more
useful, especially in high-risk individuals.
This story is likely to take an unexpected turn and
start outside the healthcare system. Pulse-detection tech-
nology is readily available in all sports retailers, and may
soon be refined to detect an irregular pulse as well. Pulse
detection is also being built into smartphones and wrist
watches, which is likely to expand personal rhythm de-
tection sooner than we think. Already, there are smart-
phone apps that recognize an irregular pulse without
any external devices such as pulse sensors. Illumination
of the pulp of one finger placed on the camera lens allows
the light sensor of the camera and the application program
to detect pulsating color changes and reveal an irregular
rhythm in 1 minute. A recent algorithm demonstrated ex-
cellent sensitivity (96.2%), specificity (97.5%), and accuracy
(96.8%) for beat-to-beat discrimination of an irregular pulse
during AF from sinus rhythm [25]. Similar systems have
already received FDA approval [26]. However caution is
essential, as recent technology with pulse sensoring algo-
rithms within a smartphone or a mobile device is less ac-
curate and less trustworthy than a multiple-lead ECG
examination, because irregular inter-beat (RR) intervals do
not always indicate AF. False-positive readings may lead
to unnecessary false alarms in healthy subjects.
Technological innovations and mobile solutions for
irregular pulse detection are likely to bypass efforts to
rigorously validate the net benefit of systematic screen-
ing campaigns to detect AF. The use of smartphones
by elderly individuals is increasing, and these peopleare aware of the age-related risk of AF and its dangers.
Most likely, there will be development of lightweight
devices connected to smartphones that will be able to
monitor heart rhythm for extended periods of time, such
as during exercise and sleep. Any efforts to restrict this
self-detection activity to physician prescription only will
be futile. These efforts would in fact be counterintuitive,
as we already encourage the elderly population to “Know
your pulse” using manual palpation. Indeed, we should
instead encourage this progress, and start preparing
the healthcare system for an increasing number of self-
detected cases of AF following self-administered pulse
detection, with or without any symptoms.
Doctors will need to answer an escalating number of
questions, such as:
 How can I ascertain whether the irregular rhythm
that was detected by my device is dangerous?
 What is the critical duration of AF periods at which
there is a risk for embolic stroke?
 My device is detecting AF more than once every
month. Should I start blood-thinning medication, and
is aspirin sufficient when I have no cardiac disease?
To answer these questions, we recommend that studies
should be carried out immediately. Evidence-based data are
needed on the later clinical course of AF once found by ad
hoc screening, and even randomized studies could be envis-
aged to assess therapy protocols to influence the risk of em-
boli after very short and infrequent episodes of AF.
Conclusion
AF detection should move forward on two fronts in
which modern technology is utilized: 1) implementation
of systematic screening of individuals who are healthy
but have risk factors for stroke, and 2) innovations in
self-administered AF or irregular pulse detection by
personal devices. It is time to prepare for an escalating
number of suspected AF cases in primary care. It has
long been suggested that AF is becoming an epidemic.
These developments will soon take the AF epidemic to
the physician’s door. This is a welcome development for
patients, physicians, and healthcare systems.
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